Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan

Diagnostic Microbiology and Infectious Disease

Volumn 34, Issue 2, 1999, Pages 123-134

  Yamaguchi, Keizo ^a   Mathai, Dilip ^b   Biedenbach, Douglas J ^b   Lewis, M Todd ^b   Gales, Ana C ^b   Jones, Ronald N ^b  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFPIROME; CEFTAZIDIME; IMIPENEM; OXACILLIN; PIPERACILLIN; SULPERAZON;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CITROBACTER FREUNDII; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; HUMAN; JAPAN; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUALITY CONTROL; SERRATIA;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; CARBAPENEMS; ENTEROBACTERIACEAE; EVALUATION STUDIES; GRAM-NEGATIVE BACTERIA; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; STAPHYLOCOCCUS;

EID: 0032974564     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(99)00019-X     Document Type: Article

References (51)

1. Barie P.S., Vogel S.B., Dellinger E.P., Rotstein O.D., Solomkin J.S., Yang J.Y., Baumgartner T.F. A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Arch Surg. 132:1997;1294-1302.
2. Barradell L.B., Bryson H.M. Cefepime A review of its antibacterial activity, pharmacokinetic properties and therapeutic use . Drugs. 47:1994;471-505.
3. Blanchard M.M., Taillon-Miller P., Nowotny P., Nowatny V. PCR buffer optimization with uniform temperature regimen to facilitate automation. PCR Method and Applications. 0:1993;234-240.
4. Bolmstrom A, Arvidson S, Ericson M, Karlsson A (1988) A novel technique for direct quantification of antimicrobial susceptibility of microorganisms (abstr. 1209). In: 28th Interscience Conference Antimicrobial Agents and Chemotherapy, Los Angeles, CA, 19988. Washington, DC: American Society for Microbiology.
5. Burwen D.R., Banerjee S.N., Gaynes R.P. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. J Infect Dis. 170:1994;1622-1625.
6. Bush K., Jacoby G.A., Medeiros A.A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 398:1995;1211-1233.
7. Coleman K., Griffin D.R., Page J.W.J., Upshon P.A. In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob Agents Chemother. 33:1989;1580-1587.
8. Jones R.N., Salazar J.C., Pfaller M.A., Doern G.V., Lozano F. Multicenter evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Colombia using the Etest method. Diagn Microbiol Infect Dis. 29:1997;265-272.
9. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science. 264:(5157):1994;375-382.
10. Fung-Tomc J.C., Gradelski E., Huczko E., Dougherty T.J., Kessler R.E., Bonner D.P. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother. 40:1996;1289-1293.
11. Hancock R.E.W., Bellido F. Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth-generation cephalosporins. J Antimicrob Chemother. 29:(Suppl A):1992;1-6.
12. Hoepelman A.I.M., Kieft H., Aoun M. International comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 32:(Suppl B):1993;175-186.
13. Ishii Y., Ohno A., Taguchi H., Imajo S., Ishiguro M., Matsuzawa. Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A β-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother. 39:1995;2269-2275.
14. Jaurequi L., Matzke D., Scott M., Minns P., Hageage G. Cefepime as treatment for osteomyelitis and other bacterial infections. J Antimicrob Chemother. 32:(Suppl B):1993;141-149.
15. Jones R.N. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 100:(Suppl 6A):1996;3S-12S.
16. Jones R.N. The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Diagn Microbiol Infect Dis. 25:1996;153-161.
17. Jones R.N., Barry A.L., Packer R.R., Gregory W.W., Thornsberry C. The cefoperazone/sulbactam combination In vitro antimicrobial spectrum, occurrence of synergy and recommendations for dilution susceptibility testing concentrations . J Clin Microbiol. 25:1987;1725-1729.
18. Jones R.N., Pfaller M.A., Doern G.V., Erwin M.E., Hollis R.J. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs A 1997 surveillance trial in 102 medical centers in the United States . Diagn Microbiol Infect Dis. 30:1998;215-228.
19. Jones R.N., Thornsberry C., Barry A.L., Ayers L., Brown S., Daniel J., Fuchs P.C., Gavan T.L., Gerlach E.H., Matsen J.M., Reller L.B., Sommers H.M. Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories. J Clin Microbiol. 20:1984;409-412.
20. Knothe H., Shah P., Kremery V., Anatal M., Mitsuhaski S. Transferable resistance to cefotaxime, cefoxitin, cefamandole, and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 11:1983;315-317.
21. Knudsen J.D., Fuursted K., Frimodt-Moller N., Espersen F. Comparison of the effect of cefepime with four cephalosporins against pneumococci with various susceptibilities to penicillin, in vitro and in the mouse peritonitis model. J Antimicrob Chemother. 40:1997;679-686.
22. Ma L., Ishii Y., Ishiguro M., Matsuzawa H., Yamaguchi K. Cloning and sequencing of the gene encoding Toho-2, a class A β-lactamase preferentially inhibited by tazobactam. Antimicrob Agents Chemother. 42:1998;1181-1186.
23. McCabe R., Chirurgi V., Farkas S.A., Haddow A., Heinz G., Greene S. A new therapeutic option for the treatment of pneumonia. Am J Med. 100:(Suppl 6A):1996;60S-67S.
24. Monnet D.L., Biddle J.W., Edwards J.R., Culver D.H., Tolson J.S., Martone W.J., Tenover F.C., Gaynes R.P. Evidence of interhospital transmission of extended-spectrum β-lactam-resistant Klebsiella pneumoniae in the United States, 1986 to 1993. Infect Control Hosp Epidemiol. 18:1997;492-498.
25. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
26. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. 1997;National Committee for Clinical Laboratory Standards, Wayne, PA.
27. Performance standards for antimicrobial susceptibility testing; Eighty informational supplement M100-S8. 1998;National Committee for Clinical Laboratory Standards, Wayne, PA.
28. Neu H.C. The crisis in antibiotic resistance. Science. 257:1992;1064-1073.
29. Neu H.C. Safety of cefepime A new extended-spectrum parenteral cephalosporin . Am J Med. 100:(Suppl 6A):1996;68S-75S.
30. Newton E.R., Yeomans E.R., Pastorek J.G. Randomized comparative study of cefepime and cefotaxime in the treatment of acute obstetric and gynecological infections. J Antimicrob Chemother. 32:(Suppl B):1993;195-204.
31. Pfaller MA, Hollis RJ, Sader HS (1992) Chromosomal restriction fragment analysis by pulsed-field gel electrophoresis. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook, vol. 2. Washington DC: American Society for Microbiology, p. 10.5c.1-12.
32. Pfaller M.A., Jones R.N., Doern G.V., Kugler K.C. Bacterial pathogens isolated from patients with blood stream infection Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997) . Antimicrob Agents Chemother. 42:1998;1762-1770.
33. Pfaller M.A., Jones R.N., Marshall S.A., Coffman S.L., Hollis R.J., Edmond M.B., Wenzel R.P. Inducible Amp C β-lactamase producing Gram-negative bacilli from blood stream infections Frequency, antimicrobial susceptibility, and molecular epidemiology in a National Surveillance Program (SCOPE) . Diagn Microbiol Infect Dis. 28:1997;211-219.
34. Pfaller M.A., Wendt C., Hollis R.J. Comparative evaluation of an automated ribotyping system versus pulsed-field gel electrophoresis for epidemiological typing of clinical isolates of Escherichia coli and Pseudomonas aeruginosa from patients with recurrent Gram-negative bacteremia. Diagn Microbiol Infect Dis. 25:1996;1-8.
35. Doern G.V., Jones R.N., Pfaller M.A., Erwin M., Ramirez-Rhonda C. Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. Diagn Microbiol Infect Dis. 30:1998;113-119.
36. Ramphal R., Gucalp R., Rotstein C., Cimino M., Oblon D. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med. 100:(Suppl 6A):1996;83S-89S.
37. Sader H.S., Mimica I., Rossi F., Zoccoli C., Montelli A.C., Sampaio J.L.M., Segura A.J.A., Magalhaes M., Nowakonski A., Mendes C.M.F. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. Diagn Microbiol Infect Dis. 28:1997;87-92.
38. Saez-Llorens X., Castano E., Garcia E., Baez C., Perez M., Tejeira F., McCracken G.H. Jr. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob Agents Chemother. 39:1995;937-940.
39. Sanders W.E., Tenney J.H., Kessler R.E. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis. 23:1996;454-461.
40. Satake S., Yoneyama H., Nakae T. Role of Omp D2 and chromosomal β-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 28:1991;199-207.
41. Schrank J.H. Jr, Kelley J.W., McAllister C.K. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with Gram-negative bacteremia. Clin Infect Dis. 20:1995;56-58.
42. Schwartz R., Das Young L.R., Ramirez-Ronda C., Frank E. Current and future management of serious skin and skin-structure infections. Am J Med. 100:(Suppl 6A):1996;90S-95S.
43. IMP) in Gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol. 34:1996;2909-2913.
44. Senda K., Arakawa Y., Nakashima K., Ito H., Ichiyama S., Shimokata K. Multifocal outbreaks of metallo-β-lactamase producing Pseudomonas aeruginosa resistant to broad-specturm β-lactams, including carbapenems. Antimicrob Agents Chemother. 40:1996;349-353.
45. Sharifi R., Geckler R., Childs S. Treatment of urinary tract infections Selecting an appropriate broad-spectrum antibiotic for nosocomial infections . Am J Med. 100:(Suppl 6A):1996;76S-82S.
46. Stunt R.A., Thomson C.J., Payne D.J., Amyes S.G.B. A study of the mechanisms involved in imipenem resistance in Pseudomonas aeruginosa isolates from Japan. J Antimicrob Chemother. 42:1998;272-273.
47. Thauvin-Eliopoulos M.C., Tripodi M.F., Moellering R.C. Jr, Eliopoulos G.M. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 41:1997;1053-1057.
48. Pfaller M.A., Jones R.N., Doern G.V. Multi-center evaluation of the antimicrobial activity for six broad-spectrum β-lactams in Venezuela using the Etest method. Diagn Microbiol Infect Dis. 30:1997;45-52.
49. Washington J.A., Jones R.N., Gerlach E.H., Murray P.R., Allen S.C., Knapp C.C. multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime. Antimicrob Agents Chemother. 37:1993;1696-1700.
50. Wilke W.W., Sutton L.D., Jones R.N. Automation of polymerase chain reaction (PCR) tests to achieve acceptable contamination rates. Clin Chem. 41:1995;622-623.
51. Yagi T., Kurokawa H., Senda K., Ichiyama S., Ito H., Ohsuka S., Shibayama K., Shimokata K., Kato N., Ohta M., Arakawa Y. Nosocomial spread of cephem-resistant Escherichia coli strains carrying multiple Toho-1-Like β-lactamase genes. Antimicrob Agent Chemother. 41:1997;2606-2611.